Cited by 2,409Glioma Diagnosis and TreatmentMedical Imaging Techniques and ApplicationsOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Response criteria for phase II studies of supratentorial malignant glioma.

Macdonald, D R, Cascino, T L, Schold, S C, Cairncross, J G·1990·Journal of Clinical Oncology

DOI 10.1200/jco.1990.8.7.1277

Open this paper in CoChat — free account

Abstract

We suggest "new" response criteria for phase II studies of supratentorial malignant glioma and favor rigorous criteria similar to those in medical oncology, with important modifications. Four response categories are proposed: complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). Response in this scheme is based on major changes in tumor size on the enhanced computed tomographic (CT) or magnetic resonance imaging (MRI) scan. Scan changes are interpreted in light of steroid use and neurologic findings. We advocate careful patient selection, emphasize pitfalls in the assessment of response, and suggest guidelines to minimize misinterpretations of response.

Integrity signals

Registry

Crossref · 10.1200/jco.1990.8.7.1277

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Successful chemotherapy for recurrent malignant oligodendroglioma
Cairncross, J. G., & Macdonald, D. R. (1988) · Annals of Neurology · doi:10.1002/ana.410230408 · Cited by 345
Self-citation
Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors
Levin, V. A., Crafts, D. C., Norman, D. M., Hoffer, P. B., Spire, J., & Wilson, C. B. (1977) · Journal of neurosurgery · doi:10.3171/jns.1977.47.3.0329 · Cited by 199
Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management.
Surbone, A., Longo, D. L., Vt, D., Ihde, D. C., Duffey, P. L., Jaffe, E. S., Solomon, D., HUBBARD, S. M., & Young, R. C. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.12.1832 · Cited by 178
Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response.
Warr, D. G., McKinney, S., & Tannock, I. F. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.9.1040 · Cited by 151
Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas
Chamberlain, M. C., Murovic, J. A., & Levin, V. A. (1988) · Neurology · doi:10.1212/wnl.38.9.1371 · Cited by 149
Steroid‐induced CT changes in patients with recurrent malignant glioma
Cairncross, J. G., Macdonald, D. R., Pexman, J. H. W., & Ives, F. J. (1988) · Neurology · doi:10.1212/wnl.38.5.724 · Cited by 100
Self-citation
Computerized tomography in the prognosis of malignant cerebral gliomas
Murovic, J. A., Turowski, K., Wilson, C. B., Hoshino, T., & Levin, V. A. (1986) · Journal of neurosurgery · doi:10.3171/jns.1986.65.6.0799 · Cited by 42
Criteria and definitions for response and relapse in children with brain tumors
Zeltzer, P. M., Friedman, H. S., Norris, D. G., & Ragab, A. H. (1985) · Cancer · doi:10.1002/1097-0142(19851001)56:7+ · Cited by 35
Post-Surgical Contrast Enhancement Mimicking Residual Brain Tumour
Cairncross, J. G., Pexman, J. H. W., & Rathbone, M. P. (1985) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100046643 · Cited by 33
Self-citation
The accuracy of volumetric measurement of high-grade gliomas
Chisholm, R. A., Stenning, S. P., & Hawkins, T. D. (1989) · Clinical Radiology · doi:10.1016/s0009-9260(89)80007-8 · Cited by 32

Flagged first, then by citations

Show all 11 references

Sorted by citations

Items 201–300 of 1,001

Correlation Between O6-Methylguanine-DNA Methyltransferase and Survival in Inoperable Newly Diagnosed Glioblastoma Patients Treated With Neoadjuvant Temozolomide
Chinot, O. L., Barrié, M., Fuentes, S., Eudes, N., Lancelot, S., Métellus, P., Muracciole, X., Braguer, D., Ouafik, L., Martin, P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.4807 · Cited by 208
Postradiation Imaging Changes in the CNS: How can we Differentiate Between Treatment Effect and Disease Progression?
Walker, A. J., Ruzevick, J., Malayeri, A. A., Rigamonti, D., Lim, M. K., Redmond, K. J., & Kleinberg, L. R. (2014) · Future Oncology · doi:10.2217/fon.13.271 · Cited by 207
A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma
Prados, M. D., Schold, S. C., Fine, H. A., Jaeckle, K. A., Hochberg, F. H., Mechtler, L. L., Fetell, M. R., Phuphanich, S., Feun, L. G., Janus, T. J., et al. (2003) · Neuro-Oncology · doi:10.1093/neuonc/5.2.96 · Cited by 207
Self-citation
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Gururangan, S., Sampson, J. H., Sathornsumetee, S., McLendon, R. E., Herndon, J. E., Marcello, J. E., Norfleet, J. A., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605412 · Cited by 205
Optimal role of temozolomide in the treatment of malignant gliomas
Stupp, R., van den Bent, M. J., & Hegi, M. E. (2005) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-005-0047-7 · Cited by 205
Incidence and risk of thromboembolism during treatment of high-grade gliomas: a prospective study
Brandes, A. A., Scelzi, E., Salmistraro, G., Ermani, M., Carollo, C., Berti, F., Zampieri, P., Baiocchi, C. B. C., & Fiorentino, M. V. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00167-6 · Cited by 204
Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study
Carpentier, A. C., Métellus, P., Ursu, R., Zohar, S., Lafitte, F., Barrié, M., Meng, Y., Richard, M., Parizot, C., Laigle–Donadey, F., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop047 · Cited by 204
Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma
Filippini, G., Falcone, C., Boiardi, A., Broggi, G., Bruzzone, M. G., Caldiroli, D., Farina, R., Farinotti, M., Fariselli, L., Finocchiaro, G., et al. (2007) · Neuro-Oncology · doi:10.1215/15228517-2007-038 · Cited by 204
Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients
Felsberg, J., Rapp, M., Loeser, S., Fimmers, R., Stummer, W., Goeppert, M., Steiger, H.-J., Friedensdorf, B., Reifenberger, G., & Sabel, M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2801 · Cited by 206
Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors
Jahnke, K., Thiel, E., Martus, P., Herrlinger, U., Weller, M., Fischer, L., Korfel, A., & on behalf of the German Primary Central Nervous System Lymphoma Study Group (G-PCNSL-SG) (2006) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9165-6 · Cited by 201
Gene Therapy for Malignant Glioma: Current Clinical Status
Pulkkanen, K. J., & Yla-Herttuala, S. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.07.357 · Cited by 161
Intraoperative Fluorescence-Guided Resection of High-Grade Malignant Gliomas Using 5-Aminolevulinic Acid–Induced Porphyrins: A Systematic Review and Meta-Analysis of Prospective Studies
Zhao, S., Wu, J., Wang, C., Liu, H., Dong, X., Chen, S., Shi, C., Liu, Y., Teng, L., Han, D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063682 · Cited by 207
Therapeutic options in recurrent glioblastoma—An update
Seystahl, K., Wick, W., & Weller, M. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.01.018 · Cited by 211
Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial
Herrlinger, U., Schäfer, N., Steinbach, J., Weyerbrock, A., Hau, P., Goldbrunner, R., Friedrich, F., Rohde, V., Ringel, F. A., Schlegel, U. S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4691 · Cited by 200
Temozolomide in malignant gliomas: current use and future targets
Villano, J. L., Seery, T. E., & Bressler, L. R. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1050-5 · Cited by 198
Assessment of Treatment Response in Patients with Glioblastoma Using O-(2-18F-Fluoroethyl)-l-Tyrosine PET in Comparison to MRI
Galldiks, N., Langen, K., Holý, R., Pinkawa, M., Stoffels, G., Nolte, K. W., Kaiser, H. J., Filss, C. P., Fink, G. R., Coenen, H. H., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.098590 · Cited by 198
Pegylated liposomal doxorubicin‐efficacy in patients with recurrent high‐grade glioma
Hau, P., Fabel, K. S., Baumgart, U., Rümmele, P., Grauer, O. M., Bock, A., Dietmaier, C., Dietmaier, W., Dietrich, J., Dudel, C., et al. (2004) · Cancer · doi:10.1002/cncr.20073 · Cited by 197
Rituximab monotherapy for patients with recurrent primary CNS lymphoma
Batchelor, T. T., Grossman, S. A., Mikkelsen, T., Ye, X., Desideri, S., & Lesser, G. J. (2011) · Neurology · doi:10.1212/wnl.0b013e31820f2d94 · Cited by 196
Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors
Sampson, J. H., Akabani, G., Archer, G. E., Berger, M. S., Coleman, R. E., Friedman, A. H., Friedman, H. S., Greer, K. L., Herndon, J. E., Kunwar, S., et al. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-012 · Cited by 196
Lessons learned in the development of targeted therapy for malignant gliomas
Omuro, A. M. P., Faivre, S. J., & Raymond, É. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0047 · Cited by 196
The role of imaging in the management of progressive glioblastoma
Ryken, T. C., Aygün, N., Morris, J., Schweizer, M. L., Nair, R., Spracklen, C. N., Kalkanis, S. N., & Olson, J. J. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1330-0 · Cited by 198
Imaging and diagnostic advances for intracranial meningiomas
Huang, R. Y., Bi, W. L., Griffith, B. D., Kaufmann, T. J., la Fougère, C. J., Schmidt, N. O., Tonn, J. C., Vogelbaum, M. A., Wen, P. Y., Aldape, K., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy143 · Cited by 196
Targeted tumor therapy with the TGF-β2 antisense compound AP 12009
SCHLINGENSIEPEN, K., SCHLINGENSIEPEN, R., STEINBRECHER, A., HAU, P., BOGDAHN, U., FISCHERBLASS, B., & JACHIMCZAK, P. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.09.002 · Cited by 195
Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features
van den Bent, M. J., Looijenga, L. H. J., Langenberg, K. P. S., Dinjens, W. N. M., Graveland, W. J., Uytdewilligen, L., Smitt, P. A. E. S., Jenkins, R. B., & Kros, J. M. (2003) · Cancer · doi:10.1002/cncr.11187 · Cited by 195
Lack of Efficacy of Bevacizumab Plus Irinotecan in Children With Recurrent Malignant Glioma and Diffuse Brainstem Glioma: A Pediatric Brain Tumor Consortium Study
Gururangan, S., Chi, S. N., Poussaint, T. Y., Onar‐Thomas, A., Gilbertson, R. J., Vajapeyam, S., Friedman, H. S., Packer, R. J., Rood, B., Boyett, J. M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.8789 · Cited by 195
Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma
Young, R. J., Gupta, A. K., Shah, A. D., Graber, J. J., Zhang, Z., Shi, W., Holodny, A. I., & Omuro, A. M. P. (2011) · Neurology · doi:10.1212/wnl.0b013e31821d74e7 · Cited by 195
Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma
Cloughesy, T. F., Landolfi, J. C., Hogan, D. J., Bloomfield, S. M., Carter, B. S., Chen, C. C., Elder, J. B., Kalkanis, S. N., Kesari, S., Lai, A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad9784 · Cited by 195
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma
Norden, A. D., Raizer, J. J., Abrey, L. E., Lamborn, K. R., Lassman, A. B., Chang, S. M., Yung, W. K. A., Gilbert, M. R., Fine, H. A., Mehta, M. P., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9948-7 · Cited by 194
Correlations Between O6-Methylguanine DNA Methyltransferase Promoter Methylation Status, 1p and 19q Deletions, and Response to Temozolomide in Anaplastic and Recurrent Oligodendroglioma: A Prospective GICNO Study
Brandes, A. A., Tosoni, A., Cavallo, G., Reni, M., Franceschi, E., Bonaldi, L., Bertorelle, R., Gardiman, M. P., Ghimenton, C., Iuzzolino, P., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3891 · Cited by 194
Diagnostic Dilemma of Pseudoprogression in the Treatment of Newly Diagnosed Glioblastomas: The Role of Assessing Relative Cerebral Blood Flow Volume and Oxygen-6-Methylguanine-DNA Methyltransferase Promoter Methylation Status
Kong, D., Kim, S. T., Kim, E.-H., Lim, D. H., Kim, W. S., Suh, Y., Lee, J.-I., Park, K., Kim, J. H., & Nam, D. (2011) · American Journal of Neuroradiology · doi:10.3174/ajnr.a2286 · Cited by 192
Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas1
Shah, G., Kesari, S. P., Xu, R., Batchelor, T. T., O'Neill, A. M., Hochberg, F. H., Levy, B., Bradshaw, J., & Wen, P. Y. (2006) · Neuro-Oncology · doi:10.1215/s1522851705000529 · Cited by 191
Response criteria for glioma
Sorensen, A. G., Batchelor, T. T., Wen, P. Y., Zhang, W., & Jain, R. K. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1204 · Cited by 191
Detection of brain metastases from small cell lung cancer
Seute, T., Leffers, P., ten Velde, G. P. M., & Twijnstra, A. (2008) · Cancer · doi:10.1002/cncr.23361 · Cited by 191
Phase I Study of GRN1005 in Recurrent Malignant Glioma
Drappatz, J., Brenner, A., Wong, E. T., Eichler, A., Schiff, D., Groves, M. D., Mikkelsen, T., Rosenfeld, S., Sarantopoulos, J., Meyers, C. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2481 · Cited by 190
Role of O -(2- 18 F-Fluoroethyl)-l-Tyrosine PET for Differentiation of Local Recurrent Brain Metastasis from Radiation Necrosis
Galldiks, N., Stoffels, G., Filß, C., Piroth, M. D., Sabel, M., Ruge, M. I., Herzog, H. R., Shah, N. J., Fink, G. R., Coenen, H. H., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.103325 · Cited by 190
Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme
Verhoeff, J. J. C., van Tellingen, O., Claes, A., Stalpers, L. J. A., Linde, M. E. V., Richel, D. J., Leenders, W. P. J., & van Furth, W. R. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-444 · Cited by 189
NOA‐03 trial of high‐dose methotrexate in primary central nervous system lymphoma: Final report
Herrlinger, U., Küker, W., Uhl, M., Blaicher, H., Karnath, H., Kanz, L., Bamberg, M., & Weller, M. (2005) · Annals of Neurology · doi:10.1002/ana.20495 · Cited by 188
Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis
Torcuator, R., Zuniga, R. M., Mohan, Y. S., Rock, J. P., Doyle, T. J., Anderson, J., Gutierrez, J., Ryu, S., Jain, R., Rosenblum, M. L., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9801-z · Cited by 187
New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: A pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials
Gorlia, T., Stupp, R., Brandes, A. A., Rampling, R., Fumoleau, P., Dittrich, C., Campone, M., Twelves, C., Raymond, É., Hegi, M. E., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.02.004 · Cited by 189
IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide
Dubbink, H. J., Taal, W., van Marion, R., Kros, J. M., van Heuvel, I., Bromberg, J. E. C., Zonnenberg, B. A., Zonnenberg, C. B. L., Postma, T. J., Gijtenbeek, J. M. M., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c34ace · Cited by 186
Therapy of glioblastoma multiforme improved by the antimutagenic chloroquine
Briceño, E., Reyes, S., & Sotelo, J. (2003) · Neurosurgical FOCUS · doi:10.3171/foc.2003.14.2.4 · Cited by 185
Recurrent Glioblastoma Treated with Bevacizumab: Contrast-enhanced T1-weighted Subtraction Maps Improve Tumor Delineation and Aid Prediction of Survival in a Multicenter Clinical Trial
Ellingson, B. M., Kim, H. J., Woodworth, D. C., Pope, W. B., Cloughesy, J. N., Harris, R. J., Lai, A., Nghiemphu, P. L., & Cloughesy, T. F. (2013) · Radiology · doi:10.1148/radiol.13131305 · Cited by 185
Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of Sulfasalazine for the treatment of progressing malignant gliomas in adults
Robe, P. A. J. T., Martin, D., Nguyen-Khac, M., Artesi, M., Deprez, M., Albert, A., Vanbelle, S., Califice, S., Bredel, M., & Bours, V. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-372 · Cited by 184
Bioinformatic profiling identifies an immune-related risk signature for glioblastoma
Cheng, W., Ren, X., Zhang, C., Cai, J., Liu, Y., Han, S., & Wu, A. (2016) · Neurology · doi:10.1212/wnl.0000000000002770 · Cited by 184
Response Assessment in Neuro-Oncology Criteria for Gliomas: Practical Approach Using Conventional and Advanced Techniques
Leao, D. J., Craig, P. G., Godoy, L. F. D. S., Leite, C. D. C., & Policeni, B. A. (2019) · American Journal of Neuroradiology · doi:10.3174/ajnr.a6358 · Cited by 184
Temozolomide for treatment-resistant recurrent meningioma
Chamberlain, M. C., Tsao-Wei, D. D., & Groshen, S. G. (2004) · Neurology · doi:10.1212/01.wnl.0000118300.82017.f4 · Cited by 184
New Treatment Strategies for Malignant Gliomas
Avgeropoulos, N. G., & Batchelor, T. T. (1999) · The Oncologist · doi:10.1634/theoncologist.4-3-209 · Cited by 182
YKL-40 and Matrix Metalloproteinase-9 as Potential Serum Biomarkers for Patients with High-Grade Gliomas
Hormigo, A., Gu, B., Karimi, S., Riedel, E., Panageas, K. S., Edgar, M. A., Tanwar, M. K., Rao, J. S., Fleisher, M., DeAngelis, L. M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0181 · Cited by 186
Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis
Almenawer, S. A., Badhiwala, J. H., Alhazzani, W. A., Greenspoon, J. N., Farrokhyar, F., Yarascavitch, B. A., Algird, A. R., Kachur, E., Cenic, A., Sharieff, W., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou349 · Cited by 180
Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Determined by Promoter Hypermethylation and Immunohistochemical Expression in Anaplastic Gliomas
Brell, M., Tortosa, A., Verger, E., Gil, J. M. G., Viñolas, N., Villà, S., Acebes, J. J., Caral, L., Pujol, T., Ferrer, I., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0230 · Cited by 180
Lessons From Anti–Vascular Endothelial Growth Factor and Anti–Vascular Endothelial Growth Factor Receptor Trials in Patients With Glioblastoma
Lu-Emerson, C., Duda, D. G., Emblem, K. E., Taylor, J. W., Gerstner, E. R., Loeffler, J. S., Batchelor, T. T., & Jain, R. K. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.9575 · Cited by 179
German Cancer Society Neuro‐Oncology Working Group NOA‐03 multicenter trial of single‐agent high‐dose methotrexate for primary central nervous system lymphoma
Herrlinger, U., Schabet, M., Brugger, W., Kortmann, R., Küker, W., Deckert, M., Engel, C., Schmeck-Lindenau, H. J., Mergenthaler, H. ‐., Krauseneck, P., et al. (2002) · Annals of Neurology · doi:10.1002/ana.10102 · Cited by 179
Apparent Diffusion Coefficient Histogram Analysis Stratifies Progression-Free Survival in Newly Diagnosed Bevacizumab-Treated Glioblastoma
Pope, W. B., Lai, A., Mehta, R. I., Kim, H. J., Qiao, J. X., Young, J. R., Xue, X., Goldin, J. G., Brown, M. S., Nghiemphu, P. L., et al. (2011) · American Journal of Neuroradiology · doi:10.3174/ajnr.a2385 · Cited by 178
Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma
Clarke, J. L., IWAMOTO, F. M., Sul, J., Panageas, K. S., Lassman, A. B., DeAngelis, L. M., Hormigo, A., Nolan, C. P., Gavrilovic, I. T., Karimi, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7944 · Cited by 178
Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery
Mathew, M., Tam, M. M., Ott, P. A., Pavlick, A. C., Rush, S. C., Donahue, B. R., Golfinos, J. G., Parker, E. C., Huang, P. P., & Narayana, A. (2013) · Melanoma Research · doi:10.1097/cmr.0b013e32835f3d90 · Cited by 178
Importance of Radiotherapy in the Outcome of Patients With Primary CNS Lymphoma: An Analysis of the CHOD/BVAM Regimen Followed by Two Different Radiotherapy Treatments
Bessell, E. M., López-Guillermo, A., Villà, S., Verger, E., Nomdedeu, B., Petit, J., Byrne, P., Montserrat, E., & Graus, F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.231 · Cited by 176
Boron Neutron Capture Therapy for Glioblastoma Multiforme: Clinical Studies in Sweden
Capala, J., Stenstam, B., Sköld, K., af Rosenschöld, P. M., Giusti, V., Persson, C., Wallin, E., Brun, A. E., Franzén, L., Carlsson, J., et al. (2003) · Journal of Neuro-Oncology · doi:10.1023/a:1023230801571 · Cited by 175
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors
Lassman, A. B., IWAMOTO, F. M., Cloughesy, T. F., Aldape, K., Rivera, A. L., Eichler, A. F., Louis, D. N., Paleologos, N. A., Fisher, B. J., Ashby, L., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor040 · Cited by 175
Self-citation
Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningiomas
Mason, W. P., Gentili, F., Macdonald, D., Hariharan, S., Cruz, C. R., & Abrey, L. E. (2002) · Journal of neurosurgery · doi:10.3171/jns.2002.97.2.0341 · Cited by 175
Self-citation
Glioblastoma in adults
Brandes, A. A., Tosoni, A., Franceschi, E., Reni, M., Gatta, G., & Vecht, C. J. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.02.005 · Cited by 174
High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial
Illerhaus, G., Kasenda, B., Ihorst, G., Egerer, G., Lamprecht, M., Keller, U. B., Wolf, H., Hirt, C., Stilgenbauer, S., Binder, M., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)30050-3 · Cited by 174
Changes in Relative Cerebral Blood Volume 1 Month after Radiation-Temozolomide Therapy Can Help Predict Overall Survival in Patients with Glioblastoma
Mangla, R., Singh, G., Ziegelitz, D., Milano, M. T., Korones, D. N., Zhong, J., & EKHOLM, S. E. (2010) · Radiology · doi:10.1148/radiol.10091440 · Cited by 173
Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas
Desjardins, A., Reardon, D. A., Herndon, J. E., Marcello, J. E., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J. H., Bailey, L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0260 · Cited by 173
A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma
Wen, P. Y., Schiff, D., Cloughesy, T. F., Raizer, J. J., Laterra, J., Smitt, M. C., Wolf, M., Oliner, K. S., Anderson, A., Zhu, M., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq198 · Cited by 179
A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma
Rampling, R., Peoples, S., Mulholland, P. J., James, A., Al‐Salihi, O., Twelves, C., McBain, C. A., Jefferies, S., Jackson, A., Stewart, W. B., Jr., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0506 · Cited by 173
Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma
Kieran, M. W., Chisholm, J., Casanova, M., Brandes, A. A., Aerts, I., Bouffet, É., Bailey, S., Leary, S. E. S., MacDonald, T. J., Mechinaud, F. M., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox109 · Cited by 173
Phase II Trial of Thalidomide and Carmustine for Patients With Recurrent High-Grade Gliomas
Fine, H. A., Wen, P. Y., Maher, E. A., Viscosi, E., Batchelor, T. T., Lakhani, N. J., Figg, W. D., Purow, B. W., & Borkowf, C. B. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.045 · Cited by 173
Immune Response in Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Intranodal Autologous Tumor Lysate-dendritic Cell Vaccination After Radiation Chemotherapy
Fadul, C. E., Fisher, J. L., Hampton, T. H., Lallana, E. C., Li, Z., Gui, J., Szczepiorkowski, Z. M., Tosteson, T. D., Rhodes, C. H., Wishart, H. A., et al. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318215e300 · Cited by 172
Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases
Freedman, R. A., Gelman, R. S., Wefel, J. S., Melisko, M., Hess, K. R., Connolly, R. M., Poznak, C. H. V., Niravath, P. A., Puhalla, S. L., Ibrahim, N. K., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.0343 · Cited by 172
Pseudoprogression and pseudoresponse: Challenges in brain tumor imaging
Clarke, J. L., & Chang, S. M. (2009) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-009-0035-4 · Cited by 171
A prospective study on glioblastoma in the elderly
Brandes, A. A., Vastola, F., Basso, U., Berti, F., Pinna, G., Rotilio, A., Gardiman, M. P., Scienza, R., Monfardini, S., & Ermani, M. (2003) · Cancer · doi:10.1002/cncr.11097 · Cited by 171
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02
Wen, P. Y., Chang, S., Lamborn, K. R., Kuhn, J. G., Norden, A. D., Cloughesy, T. F., Robins, H. I., Lieberman, F. S., Gilbert, M. R., Mehta, M. P., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not247 · Cited by 174
From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors?
Galldiks, N., Langen, K., & Pope, W. B. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov118 · Cited by 171
Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma
Wheeler, L. A., Manzanera, A. G., Bell, S. D., Cavaliere, R., McGregor, J. M., Grecula, J. C., Newton, H. B., Lo, S. S.-M., Badie, B., Portnow, J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now002 · Cited by 176
Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma
Boockvar, J. A., Tsiouris, A. J., Hofstetter, C. P., Kovanlikaya, I., Fralin, S. R., Kesavabhotla, K., Seedial, S. M., Pannullo, S. C., Schwartz, T. H., Stieg, P. E., et al. (2010) · Journal of neurosurgery · doi:10.3171/2010.9.jns101223 · Cited by 170
Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab
Lee, E. Q., Norden, A. D., Drappatz, J., Muzikansky, A., Doherty, L. M., LaFrankie, D. C., Ciampa, A. S., Kesari, S., & Wen, P. Y. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-006 · Cited by 170
Molecular Markers in Low-Grade Gliomas: Predictive or Prognostic?
Hartmann, C. J., Hentschel, B., Tatagiba, M. S., Schramm, J., Schnell, O., Seidel, C., Stein, R. J., Reifenberger, G., Pietsch, T., von Deimling, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3194 · Cited by 170
Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC
Cloughesy, T. F., Landolfi, J. C., Vogelbaum, M. A., Ostertag, D. G., Elder, J. B., Bloomfield, S. M., Carter, B. S., Chen, C. C., Kalkanis, S. N., Kesari, S., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy075 · Cited by 170
Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-l-tyrosine PET in comparison to MRI
Galldiks, N., Rapp, M., Stoffels, G., Fink, G. R., Shah, N. J., Coenen, H. H., Sabel, M., & Langen, K. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2251-4 · Cited by 169
BRAFV600E mutation is a negative prognosticator in pediatric ganglioglioma
Dahiya, S. M., Haydon, D. H., Alvarado, D. M., Gurnett, C. A., Gutmann, D. H., & Leonard, J. R. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1120-y · Cited by 167
Brain Tumor Imaging in Clinical Trials
Henson, J. W., Ulmer, S., & Harris, G. J. (2008) · American Journal of Neuroradiology · doi:10.3174/ajnr.a0963 · Cited by 167
Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas
Doherty, L. M., Gigas, D. C., Kesari, S., Drappatz, J., Kim, R., Zimmerman, J., Ostrowsky, L., & Wen, P. Y. (2006) · Neurology · doi:10.1212/01.wnl.0000223844.77636.29 · Cited by 166
Phase II Trial of Lomustine Plus Temozolomide Chemotherapy in Addition to Radiotherapy in Newly Diagnosed Glioblastoma: UKT-03
Herrlinger, U., Rieger, J., Koch, D., Loeser, S., Blaschke, B., Kortmann, R., Steinbach, J. P., Hundsberger, T., Wick, W., Meyermann, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.9104 · Cited by 166
Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Radiation Therapy and Concomitant Temozolomide: Comparison Study of Standard and High-b-Value Diffusion-weighted Imaging
Chu, H. H., Choi, S. H., Ryoo, I., Kim, S. C., Yeom, J. A., Shin, H., Jung, S. C., Lee, A. L., Yoon, T. J., Kim, T. M., et al. (2013) · Radiology · doi:10.1148/radiol.13122024 · Cited by 166
Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients
Wang, J. Z., Landry, A., Raleigh, D. R., Sahm, F., Walsh, K. M., Goldbrunner, R., Yefet, L. S., Tonn, J. C., Gui, C., Ostrom, Q. T., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae082 · Cited by 165
Temozolomide as salvage treatment in primary brain lymphomas
Reni, M., Zaja, F. F., Mason, W. P., Perry, J., Mazza, E. A., Spina, M., Bordonaro, R., Ilariucci, F., Faedi, M., Corazzelli, G., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603660 · Cited by 164
Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972
van den Bent, M. J., Chinot, O. L., Boogerd, W. J., Marques, J. B., TAPHOORN, M. J. B., Kros, J. M., van der Rijt, C. C. D., Vecht, C. J., Beule, N. D., & Barón, B. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg157 · Cited by 164
Anti-angiogenic therapy for high-grade glioma
Ameratunga, M., Pavlakis, N., Wheeler, H., Grant, R., Simes, J. R., & Khasraw, M. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008218.pub4 · Cited by 168
Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival
Gahramanov, S., Muldoon, L. L., Varallyay, C. G., Li, X., Kraemer, D. F., Fu, R., Hamilton, B. E., Rooney, W. D., & Neuwelt, E. A. (2013) · Radiology · doi:10.1148/radiol.12111472 · Cited by 162
Pitfalls in the Neuroimaging of Glioblastoma in the Era of Antiangiogenic and Immuno/Targeted Therapy – Detecting Illusive Disease, Defining Response
Huang, R. Y., Neagu, M. R., Reardon, D. A., & Wen, P. Y. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00033 · Cited by 163
Medical management of brain tumors and the sequelae of treatment
Schiff, D., Lee, E. Q., Nayak, L., Norden, A. D., Reardon, D. A., & Wen, P. Y. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou304 · Cited by 170
Phase II Study of Protracted Daily Temozolomide for Low-Grade Gliomas in Adults
Kesari, S., Schiff, D., Drappatz, J., LaFrankie, D. C., Doherty, L. M., Macklin, E. A., Muzikansky, A., Santagata, S., Ligon, K. L., Norden, A. D., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0888 · Cited by 162
PCV Chemotherapy for Recurrent Oligodendrogliomas and Oligoastrocytomas
Soffietti, R., Rudà, R., Bradač, G. B., & Schiffer, D. (1998) · Neurosurgery · doi:10.1097/00006123-199811000-00035 · Cited by 161
A Review of VEGF/VEGFR-Targeted Therapeutics for Recurrent Glioblastoma
Reardon, D. A., Turner, S., Peters, K. B., Desjardins, A., Gururangan, S., Sampson, J. H., McLendon, R. E., Herndon, J. E., Jones, L. W., Kirkpatrick, J. P., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0038 · Cited by 160
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)
Wen, P. Y., Yung, W. K. A., Lamborn, K. R., Norden, A. D., Cloughesy, T. F., Abrey, L. E., Fine, H. A., Chang, S. M., Robins, H. I., Fink, K., et al. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-010 · Cited by 160
Surgical resection of malignant gliomas—role in optimizing patient outcome
Eyüpoglu, I. Y., Buchfelder, M., & Savaskan, N. E. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.279 · Cited by 166
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
Wick, W., Gorlia, T., Bady, P., Platten, M., van den Bent, M. J., TAPHOORN, M. J. B., Steuve, J., Brandes, A. A., Hamou, M., Wick, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3153 · Cited by 164
Differentiating Tumor Progression from Pseudoprogression in Patients with Glioblastomas Using Diffusion Tensor Imaging and Dynamic Susceptibility Contrast MRI
Wang, S., Martinez‐Lage, M., Sakai, Y., Chawla, S., Kim, S. G., Alonso‐Basanta, M., Lustig, R. A., Brem, S. S., Mohan, S., Wolf, R. L., et al. (2015) · American Journal of Neuroradiology · doi:10.3174/ajnr.a4474 · Cited by 159
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study
Pope, W. B., Qiao, X., Kim, H. J., Lai, A., Nghiemphu, P. L., Xue, X., Ellingson, B. M., Schiff, D., Aregawi, D. G., Cha, S., et al. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0847-y · Cited by 158
Methylation of O6-Methylguanine DNA Methyltransferase and Loss of Heterozygosity on 19q and/or 17p Are Overlapping Features of Secondary Glioblastomas with Prolonged Survival
Eoli, M., Menghi, F., Bruzzone, M. G., Simone, T. D., Valletta, L., Pollo, B., Bissola, L., Silvani, A., Bianchessi, D., D’Incerti, L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2184 · Cited by 158

Authors: Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G.
Affiliations: Western University (CA)
ORCID: Cairncross, J G
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 1990-07
Volume: 8
Issue: 7
Pages: 1277-1280
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.1990.8.7.1277
OpenAlex: W1959628099
Cited by: 2,409
References: 11
Citations by year: 2026: 31 · 2025: 21 · 2024: 36 · 2023: 52 · 2022: 53 · 2021: 59 · 2020: 68 · 2019: 75 · 2018: 97 · 2017: 111 · 2016: 125 · 2015: 122 · 2014: 161 · 2013: 186 · 2012: 145
FWCI: 3.90
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords: high-grade glioma, supratentorial glioma, response criteria, tumor size measurement, complete response, partial response, stable disease, progressive disease, steroid use, neurologic findings, patient selection, magnetic resonance imaging, computed tomography
MeSH terms: Diagnostic Errors, Drug Evaluation, Glioma, Humans, Magnetic Resonance Imaging, Medical Oncology, Tomography, X-Ray Computed, Supratentorial Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Response criteria for phase II studies of supratentorial malignant glioma.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks